The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
Open accessAbstract
Purpose: Fludarabine and cyclophosphamide (FC), which are active in treatment of chronic lymphocytic leukemia (CLL), are synergistic with the monoclonal antibody rituximab in vitro in lymphoma cell lines. A chemoimmunotherapy program consisting of fludarabine, cyclophosphamide, and rituximab (FCR) was developed with the goal of increasing the complete remission (CR) rate in previously untreated CLL patients to ≥ 50%. Patients and Methods: We conducted a single-arm study of FCR as initial therapy in 224 patients with progressive or advanced CLL. Flow cytometry was used to measure residual disease. Results and safety were compared with a previous regimen using FC. Results: The median age was 58 years; 75 patients (33%) had Rai stage III to IV disease. The CR rate was 70% (95% CI, 63% to 76%), the nodular partial remission rate was 10%, and the partial remission rate was 15%, for an overall response rate of 95% (95% CI, 92% to 98%). Two thirds of patients evaluated with flow cytometry had less than 1% CD5- and CD19-coexpressing cells in bone marrow after therapy. Grade 3 to 4 neutropenia occurred during 52% of courses; major and minor infections were seen in 2.6% and 10% of courses, respectively. One third of the 224 patients had ≥ one episode of infection, and 10% had a fever of unknown origin. Conclusion: FCR produced a high CR rate in previously untreated CLL. Most patients had no detectable disease on flow cytometry at the end of therapy. Time to treatment failure analysis showed that 69% of patients were projected to be failure free at 4 years (95% CI, 57% to 81%).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Self-citationFludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
Rai, K. R., Peterson, B. L., Appelbaum, F. R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G. A., Larson, R. A., Cheson, B. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012143432402 · Cited by 1,001
Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 604
Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia
O’Brien, S. M., Kantarjian, H., Thomas, D. A., Giles, F. J., Freireich, E. J., Cortes, J., Lerner, S., & Keating, M. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2165 · Cited by 586
Self-citationByrd, J. C. (2003) · Blood · doi:10.1182/blood-2002-04-1258 · Cited by 571
Byrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A., Park, K., Pearson, M., Waselenko, J. K., Ling, G., Grever, M. R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2153 · Cited by 508
The French Cooperative Group on CLL, Johnson, S., Smith, A. G., Löffler, H., Ösby, E., Juliusson, G., Emmerich, B., Wyld, P. J., & Hiddemann, W. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91681-5 · Cited by 434
Byrd, J. C. (2005) · Blood · doi:10.1182/blood-2004-03-0796 · Cited by 404
Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., & Bonavida, B. (1997) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1997.12.177 · Cited by 394
Rituximab: Mechanism of action and resistance
Maloney, D. G., Smith, B., & Rose, A. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30156 · Cited by 375
Hainsworth, J. D., Litchy, S., Barton, J. H., Houston, G. A., Hermann, R. C., Bradof, J. E., & Greco, F. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.027 · Cited by 351
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Huhn, D. (2001) · Blood · doi:10.1182/blood.v98.5.1326 · Cited by 347
Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia
O’Brien, S. M., Kantarjian, H. M., Cortes, J., Beran, M., Koller, C. A., Giles, F. J., Lerner, S., & Keating, M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1414 · Cited by 347
Self-citationRawstron, A. C., Kennedy, B., Evans, P. A. S., Davies, F. E., Richards, S. J., Haynes, A. P., Russell, N. H., Hale, G., Morgan, G. J., Jack, A. S., et al. (2001) · Blood · doi:10.1182/blood.v98.1.29 · Cited by 269
Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
Bryant, J., & Day, R. (1995) · Biometrics · doi:10.2307/2533268 · Cited by 260
Flinn, I. W., Byrd, J. C., Morrison, C., Jamison, J., Diehl, L. F., Murphy, T. J., Piantadosi, S., SEIFTER, E. J., Ambinder, R. F., Vogelsang, G. B., et al. (2000) · Blood · doi:10.1182/blood.v96.1.71 · Cited by 256
Manshouri, T., Do, K.-A., Wang, X., Giles, F. J., O'Brien, S. M., Saffer, H., Thomas, D., Jilani, I., Kantarjian, H. M., Keating, M. J., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1639 · Cited by 204
Self-citationDi Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J., & Introna, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03014.x · Cited by 198
Yamauchi, T., Nowak, B. J., Keating, M. J., & Plunkett, W. K. (2001) · PubMed · Cited by 192
Self-citationBosch, F., Ferrer, A., López‐Guillermo, A., Giné, E., Bellosillo, B., Villamor, N., Colomer, D., Cobo, F., Perales, M., Esteve, J., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03959.x · Cited by 181
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Patients Treated with Fludarabine
Ramondo, F. D., Giustolisi, R., Cacciola, E., et al. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309054731 · Cited by 101
Huh, Y. O., Keating, M. J., Saffer, H. L., Jilani, I. B., Lerner, S. A., & Albitar, M. X. (2001) · American Journal of Clinical Pathology · doi:10.1309/438n-e0fh-a5pr-xcac · Cited by 82
Self-citationPotentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
Alas, S., Bonavida, B., & Emmanouilides, C. E. (2000) · PubMed · Cited by 68
Clavio, M., Miglino, M. A., Spriano, M., Pietrasanta, D., Vallebella, E., Celesti, L., Canepa, L., Pierri, I., Cavalierè, M., Ballerini, F., et al. (1998) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1998.tb01084.x · Cited by 24
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61381-5 · Cited by 1,888
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,050
Rituximab: Mechanism of Action
Weiner, G. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.011 · Cited by 786
Tam, C. S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.-A., Thomas, D. A., Cortes, J., Lerner, S., & Keating, M. J. (2008) · Blood · doi:10.1182/blood-2008-02-140582 · Cited by 693
Self-citation
Metadata
- Authors
- Keating, M. J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., Koller, C., Wierda, W., Detry, M. A., Lynn, A., & Kantarjian, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-06-20
- Volume
- 23
- Issue
- 18
- Pages
- 4079-4088
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2125134816
- Cited by
- 950
- References
- 27
- FWCI
- 35.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.